I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes prevalence in Morocco is estimated to be 6.4%.\[[@ref1]\] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.\[[@ref2]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref3]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref4]\] This short communication presents the results for patients enrolled from Marrakech, Morocco.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 196 patients were enrolled in the study. The patient characteristics for the entire cohort, divided as insulin-naïve and insulin users is shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients (42.3%) started on or were switched to insulin detemir. Other groups were biphasic insulin aspart (*n* = 71), insulin aspart (*n* = 5), basal insulin plus insulin aspart (*n* = 14) and other insulin combinations (*n* = 23).

###### 

Overall demographic data

![](IJEM-17-404-g001)

After 24 weeks of treatment, overall hypoglycaemic events or episodes reduced from 10.3 events/patient-year to 7.2 events/patient-year in insulin user group whereas overall hypoglycaemia increased from 0.4 events/patient-year to 2.3 events/patient-year in the insulin naïve group. However, this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline. SADRs including major hypoglycaemic events did not occur in any of the study patients. Blood pressure decreased from baseline while overall lipid profile and quality of life improved after 24 weeks \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall safety data

![](IJEM-17-404-g002)

###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in the total cohort \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data

![](IJEM-17-404-g004)

Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 71 patients started on biphasic insulin aspart ± OGLD, of which 38 (53.5%) were insulin naïve and 33 (46.5%) were insulin users. After 24 weeks of treatment, hypoglycaemic events or episodes increased for both the groups (insulin naïve: from 0.7 events/patient-year to 3.7 events/patient-year and insulin users: from 9.1 events/patient-year to 10.0 events/patient-year). An increase in body weight was observed for both the groups. Quality of life improved at the end of the study \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose

![](IJEM-17-404-g006)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-404-g007)

Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 14 patients started on or switched to basal + insulin aspart ± OGLD, of which 1 (7.1%) was insulin naïve and 13 (92.9%) were insulin users. After 24 weeks of treatment, hypoglycemia reduced from 11.0 events/participant-year to 0.0 events/participant-year \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-404-g008)

###### 

Insulin dose

![](IJEM-17-404-g009)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-404-g010)

Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 83 patients started on insulin detemir ± OGLD, of which 74 (89.2%) were insulin naïve and 9 (10.8%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemic events reduced from 2.9 events/patient-year to 1.9 events/patient-year in insulin user group while hypoglycaemia increased from 0.4 events/patient-year to 0.6 events/patient-year in insulin naïve group. Quality of life improved at 24 weeks \[Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data
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###### 

Insulin dose

![](IJEM-17-404-g012)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data

![](IJEM-17-404-g013)

Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 5 patients started on insulin aspart ± OGLD of which 1 (20.0%) was insulin naïve and 4 (80.0%) were insulin users. After 24 weeks of treatment, hypoglycaemic events reduced from 6.5 events/patient-year to 4.3 events/patient-year in insulin user group. Mean HbA~1~c and mean FPG improved from baseline to study end who started on or were switched to insulin aspart ± OGLDs for insulin user group. Quality of life improved in both insulin naïve and insulin user groups.

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control and quality of life following 24 weeks of treatment with any of the insulin analogues (Biphasic insulin aspart; Basal + insulin aspart; insulin detemir; Insulin aspart) with or without OGLD. SADR\'s including major hypoglycaemic events did not occur in any of the study patients. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Marrakech, Morocco.
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